Liu Hui,Halimulati Huxitaer,Li Wanfu,et al.Analysis of the efficacy of living donor liver transplantation in the treatment of pediatric inborn errors of metabolism[J].Journal of Clinical Pediatric Surgery,2025,(03):220-225.[doi:10.3760/cma.j.cn101785-202501006-004]
亲体肝移植治疗儿童遗传代谢病的疗效分析
- Title:
- Analysis of the efficacy of living donor liver transplantation in the treatment of pediatric inborn errors of metabolism
- Keywords:
- Living Donor Liver Transplantation; Inborn Errors of Metabolism; Surgical Procedures; Operative; Child
- 摘要:
- 目的 分析亲体肝移植治疗儿童遗传代谢病(inborn errors of metabolism,IEM)的临床效果。方法 回顾性分析新疆医科大学第一附属医院2021年1月至2024年7月间18例行亲体肝移植手术的遗传代谢病患儿(为遗传代谢病组)临床资料,分析其治疗效果及并发症情况,并与本中心同期21例行亲体肝移植的非遗传代谢病患儿(为非遗传代谢病组)进行术前资料与累计生存率的比较,同时比较遗传代谢病组患儿术前、术后6个月的体重Z评分、身高Z评分。结果 18例遗传代谢病患儿原发病包括:肝豆状核变性8例、酪氨酸血症2例、先天性肝纤维化4例、枫糖尿病1例、Caroli病1例、糖原累积症Ⅰ型1例、Alagille综合征1例。遗传代谢病组患儿与非遗传代谢病组患儿移植月龄分别为114.00(96.00,132.00)个月、6.57(5.68,77.00)个月,身高Z评分分别为(-0.77±1.62)分、(-1.91±2.30)分;差异均有统计学意义(P＜0.05)。遗传代谢病组中术后有7例出现不同程度并发症,经对症治疗后治愈;1例围手术期因弥散性血管内凝血死亡。两组中位随访时间19.75个月,遗传代谢病组与非遗传代谢病组患儿术后累计生存率分别为87.5%和84.6%,差异无统计学意义(P>0.05);遗传代谢病组术前和术后6个月身高、体重Z评分分别为(-0.77±1.62)分和(-1.22±2.26)分、(-0.27±1.29)分和(0.03±0.92)分,差异均具有统计学意义(P＜0.05)。结论 亲体肝移植可以有效治疗部分遗传代谢病,改善患儿生长发育迟缓,提高患儿的生存率和生活质量。
- Abstract:
- Objective To analyze the clinical outcomes of living donor liver transplantation in the treatment of pediatric inborn errors of metabolism (IEM).Methods A retrospective analysis was conducted on the clinical data of 18 pediatric patients with IEM who underwent living donor liver transplantation at the First Affiliated Hospital of Xinjiang Medical University from January 2021 to July 2024 (IEM group).The treatment outcomes and postoperative complications were analyzed and compared with 21 pediatric patients without IEM who underwent living donor liver transplantation at the same period (non-IEM group).Preoperative clinical data and cumulative survival rates were compared between the two groups,as well as changes in weight Z-scores and height Z-scores in the IEM group before surgery and at six months postoperatively. Results Among the 18 pediatric patients with IEM,the primary diseases included Wilson’s disease (n=8),tyrosinemia (n=2),congenital hepatic fibrosis (n=4),maple syrup urine disease (n=1),Caroli disease (n=1),glycogen storage disease type Ⅰ (n=1),and Alagille syndrome (n=1).The median age at transplantation in the IEM and non-IEM groups was 114.00 (96.00,132.00) months and 6.57 (5.68,77.00) months,respectively,and the height Z-scores were (-0.77±1.62) and (-1.91±2.30),respectively.These differences were statistically significant (P<0.05).Postoperatively,seven patients in the IEM group experienced varying degrees of complications,all of whom recovered after symptomatic treatment.One patient died in the perioperative period due to disseminated intravascular coagulation.The median follow-up period was 19.75 months.The cumulative postoperative survival rates in the IEM and non-IEM groups were 87.5% and 84.6%,respectively,with no statistically significant difference (P>0.05).In the IEM group,the height and weight Z-scores before surgery and six months postoperatively were (-0.77±1.62) vs.(-1.22±2.26) and (-0.27±1.29) vs.(0.03±0.92),respectively,with statistically significant differences (P<0.05). Conclusions Living donor liver transplantation is an effective treatment for certain inborn errors of metabolism,significantly improving growth and development in affected children while enhancing survival rates and quality of life.
参考文献/References:
[1] 夏强,朱欣烨.儿童肝移植发展现状及展望[J].临床小儿外科杂志,2022,21(5):401-404.DOI:10.3760/cma.j.cn101785-202202028-001. Xia Q,Zhu XY.Current development and future outlook of pediatric liver transplantation[J].DOI:10.3760/cma.j.cn101785-202202028-001.
[2] 库尔班江·阿布都西库尔,王建设.遗传代谢性疾病与肝移植[J].中华肝脏病杂志,2019,27(3):166-171.DOI:10.3760/cma.j.issn.1007-3418.2019.03.002. Abuduxikuer KEBJ,Wang JS.Inherited metabolic diseases and liver transplantation[J].Chin J Hepatol,2019,27(3):166-171.DOI:10.3760/cma.j.issn.1007-3418.2019.03.002.
[3] Kasahara M,Sakamoto S,Fukuda A.Pediatric living-donor liver transplantation[J].Semin Pediatr Surg,2017,26(4):224-232.DOI:10.1053/j.sempedsurg.2017.07.008.
[4] Kuczmarski RJ,Ogden CL,Grummer-Strawn LM,et al.CDC growth charts:United States[J].Adv Data,2000,(314):1-27.
[5] Oishi K,Arnon R,Wasserstein MP,et al.Liver transplantation for pediatric inherited metabolic disorders:considerations for indications,complications,and perioperative management[J].Pediatr Transplant,2016,20(6):756-769.DOI:10.1111/petr.12741.
[6] 刘辉,古力米热木·买买提江,李万富,等.儿童亲体肝移植11例回顾性分析[J].临床小儿外科杂志,2023,22(12):1124-1129.DOI:10.3760/cma.j.cn101785-202306008-006. Liu H,Maimaitijiang GLMRM,Li WF,et al.Experiences of pro-liver transplantation in children:a report of 11 cases[J].J Clin Ped Sur,2023,22(12):1124-1129.DOI:10.3760/cma.j.cn101785-202306008-006.
[7] Rawal N,Yazigi N.Pediatric liver transplantation[J].Pediatr Clin North Am,2017,64(3):677-684.DOI:10.1016/j.pcl.2017.02.003.
[8] 孙丽莹,朱志军,魏林,等.肝移植治疗儿童遗传代谢性疾病42例[J].中华器官移植杂志,2017,38(6):337-342.DOI:10.3760/cma.j.issn.0254-1785.2017.06.004. Sun LY,Zhu ZJ,Wei L,et al.Pediatric liver transplantation for metabolic liver disease:report of 42 cases[J].Chin J Organ Transplant,2017,38(6):337-342.DOI:10.3760/cma.j.issn.0254-1785.2017.06.004.
[9] Kasahara M,Sakamoto S,Horikawa R,et al.Living donor liver transplantation for pediatric patients with metabolic disorders:the Japanese multicenter registry[J].Pediatr Transplant,2014,18(1):6-15.DOI:10.1111/petr.12196.
[10] Schilsky ML.Wilson disease:diagnosis,treatment,and follow-up[J].Clin Liver Dis,2017,21(4):755-767.DOI:10.1016/j.cld.2017.06.011.
[11] Dong Y,Wu ZY.Challenges and suggestions for precise diagnosis and treatment of Wilson’s disease[J].World J Pediatr,2021,17(6):561-565.DOI:10.1007/s12519-021-00475-4.
[12] 中华医学会肝病学分会遗传代谢性肝病协作组.肝豆状核变性诊疗指南(2022年版)[J].中华肝脏病杂志,2022,30(1):9-20.DOI:10.3760/cma.j.cn501113-20211217-00603. Inherited Metabolic Liver Disease Collaboration Group,Chinese Society of Hepatology,Chinese Medical Association.Guidelines for the diagnosis and treatment of hepatolenticular degeneration (2022 edition)[J].Chin J Hepatol,2022,30(1):9-20.DOI:10.3760/cma.j.cn501113-20211217-00603.
[13] Irie R,Nakazawa A,Sakamoto S,et al.Living donor liver transplantation for congenital hepatic fibrosis in children[J].Pathol Int,2020,70(6):348-354.DOI:10.1111/pin.12917.
[14] Desmet VJ.Ludwig symposium on biliary disorders-part I.Pathogenesis of ductal plate abnormalities[J].Mayo Clin Proc,1998,73(1):80-89.DOI:10.4065/73.1.80.
[15] Feier F,Schwartz IVD,Benkert AR,et al.Living related versus deceased donor liver transplantation for maple syrup urine disease[J].Mol Genet Metab,2016,117(3):336-343.DOI:10.1016/j.ymgme.2016.01.005.
[16] Hori T,Egawa H,Takada Y,et al.Long-term outcomes after living-donor liver transplantation for Alagille syndrome:a single center 20-year experience in Japan[J].Am J Transplant,2010,10(8):1951-1952.DOI:10.1111/j.1600-6143.2010.03196.x.
[17] Arnon R,Kerkar N,Davis MK,et al.Liver transplantation in children with metabolic diseases:the studies of pediatric liver transplantation experience[J].Pediatr Transplant,2010,14(6):796-805.DOI:10.1111/j.1399-3046.2010.01339.x.
备注/Memo
收稿日期:2025-1-3。
基金项目:2023天山英才人才培养计划(TSYC202301A072);新疆维吾尔自治区重点研发任务专项项目资助(2023B03018—2);新疆医科大学第一附属医院2023年青年科研启航专项基金(2023YFY—QKQN—10)
通讯作者:李万富,Email:13699982169@163.com